Ashwagandha KSM-66: What the Clinical Trials Actually Show

Ashwagandha: Separating Evidence from Tradition

Ashwagandha (Withania somnifera) is an Ayurvedic medicinal herb that has been used in traditional Indian medicine for thousands of years. In the last two decades, it has accumulated a meaningful body of modern clinical evidence — particularly when standardised extracts are used. The key phrase is standardised extract: not all ashwagandha products are equivalent, and the clinical evidence is concentrated in specific preparations.

What KSM-66 Is

KSM-66 is a full-spectrum ashwagandha root extract developed by Ixoreal Biomed and standardised to a minimum of 5% withanolides, the primary bioactive compounds in ashwagandha. Unlike extracts made from roots and leaves combined (which are higher in withanolide content but potentially less clinically predictable), KSM-66 uses only the root, maintaining the traditional application of the herb.

The majority of well-designed human clinical trials on ashwagandha — particularly those on cortisol, stress, and testosterone — have used KSM-66 or the closely related Sensoril extract (a root-and-leaf preparation standardised to withanolide glycosides). When evaluating research or selecting a product, checking the specific extract used in trials is essential.

Cortisol Reduction: The Chandrasekhar 2012 Trial

The most frequently cited study on ashwagandha and stress is the randomised, double-blind, placebo-controlled trial by Chandrasekhar et al. (2012), published in the Indian Journal of Psychological Medicine. Sixty adults with a history of chronic stress were randomised to 300 mg of KSM-66 twice daily (600 mg total) or placebo for 60 days.

The KSM-66 group demonstrated a 27.9% reduction in serum cortisol levels compared to 7.9% in the placebo group. Stress scores on validated scales (PSS, GHQ-28) improved significantly. Subjective reports of anxiety, energy levels, and general wellbeing also favoured the active group. This was not a trivial or marginal finding — a 27.9% reduction in a physiologically significant stress biomarker represents a meaningful clinical effect.

Sleep: The Langade 2020 Trial

Langade et al. (2020) conducted a randomised, double-blind, placebo-controlled trial of 300 mg KSM-66 taken twice daily in 150 healthy adults with non-restorative sleep. After 8 weeks, the ashwagandha group showed significant improvements in sleep onset latency, total sleep time, sleep efficiency, and morning alertness, as well as reduced anxiety scores. The effect was consistent across subjective reports and actigraphy (objective sleep monitoring). Sleep efficiency improved from approximately 72% to 79% in the treatment group versus minimal change in placebo.

Testosterone and Reproductive Health

Several trials — predominantly in men with low-normal or stress-reduced testosterone levels — have found that ashwagandha supplementation increases testosterone by 10–22%. A 2019 trial in overweight men aged 40–70 with mild fatigue found that 300 mg KSM-66 twice daily for 8 weeks significantly increased DHEA-S and testosterone compared to placebo. A 2010 study in men with oligospermia found improvements in sperm count, motility, and testosterone after 3 months at 5 g of raw root powder.

The effect appears most pronounced in men under physiological stress or with below-average baseline testosterone. The mechanism is thought to involve HPA axis modulation — reducing cortisol, which at elevated levels suppresses hypothalamic GnRH secretion and thereby downstream testosterone synthesis.

Timing, Dosing, and Onset

The standard clinical dose is 300–600 mg of KSM-66 extract daily. Some trials divide this into two doses; others use a single dose. The effects are not immediate — the full benefit for stress, cortisol, and sleep typically manifests over 4–8 weeks of consistent use.

The Thyroid Caution

Ashwagandha has been classified as a thyroid-stimulating agent in preclinical research and case reports. Several case studies describe hyperthyroidism-like symptoms or abnormal thyroid function tests in individuals taking ashwagandha. People with pre-existing thyroid conditions — hypothyroidism, hyperthyroidism, Hashimoto's thyroiditis — or those taking thyroid medications should consult a physician before use. The risk is probably low but the consequence of thyroid disruption is significant enough to warrant caution. Similarly, ashwagandha should be avoided during pregnancy.